ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Michigan Spin-Off Signs With Medivation

by Michael McCoy
May 5, 2014 | APPEARED IN VOLUME 92, ISSUE 18

OncoFusion Therapeutics, an oncology drug company formed in 2012 by two University of Michigan professors, has signed a licensing agreement with the San Francisco-based biotech firm Medivation. The deal gives Medivation rights to develop and commercialize compounds discovered by OncoFusion that target bromodomain and extraterminal proteins, which regulate genes and play a role in cancer. Medivation is involved in a lawsuit with professors from the University of California, Los Angeles, over a similar compound licensing agreement (C&EN, April 21, page 8).

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment